MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Phase 2

Completed

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Malignant Solid Neoplasm

Interventions: Drug: Cannabidiol
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-05-24

Last Posted Date: 2024-04-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT05388058

Locations: 🇺🇸
Fairview Range Medical Center, Hibbing, Minnesota, United States
🇺🇸
Mayo Clinic Health System Albert Lea, Albert Lea, Minnesota, United States
🇺🇸
Mayo Clinic Health System Mankato, Mankato, Minnesota, United States

and more 6 locations

Health Care Provider Preventiomter Study

Not Applicable

Withdrawn

Conditions: Wellness

Interventions: Behavioral: Preventiometer device with wellness coaching

First Posted Date: 2022-05-24

Last Posted Date: 2024-06-27

Lead Sponsor: Mayo Clinic

Registration Number: NCT05387590

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Education for Prevention of Melanoma in Hispanic Populations

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Other: Educational Intervention
Other: Questionnaire Administration

First Posted Date: 2022-05-24

Last Posted Date: 2024-12-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 145

Registration Number: NCT05388851

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases from BRAF V600 Mutated Metastatic Melanoma

Phase 1

Active, not recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC V8
Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Neoplasm in the Central Nervous System
Metastatic Melanoma

Interventions: Drug: Dabrafenib
Drug: MEK-1/MEKK-1 Inhibitor E6201
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2022-05-24

Last Posted Date: 2025-02-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT05388877

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Richter Syndrome
Small Lymphocytic Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Durvalumab
Drug: Venetoclax
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Positron Emission Tomography (PET)
Procedure: Computed Tomography

First Posted Date: 2022-05-24

Last Posted Date: 2025-04-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 33

Registration Number: NCT05388006

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Intracardiac Flow Assessment in Cardiac Amyloidosis

Recruiting

Conditions: Amyloidosis Cardiac
Healthy Adults

Interventions: Diagnostic Test: Cardiac magnetic resonance image (CMR)
Diagnostic Test: Transthoracic Echocardiogram (TTE)
Diagnostic Test: Six-minute Walk Test

First Posted Date: 2022-05-18

Last Posted Date: 2025-01-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 100

Registration Number: NCT05379101

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

PR3-AAV Resilient Remission or PRRR

Phase 2

Terminated

Conditions: Granulomatosis With Polyangiitis
ANCA Associated Vasculitis
Microscopic Polyangiitis

Interventions: Drug: Obinutuzumab
Drug: Rituximab

First Posted Date: 2022-05-17

Last Posted Date: 2024-07-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 6

Registration Number: NCT05376319

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

BFR After Biceps Tendon Repair and MPFLR

Not Applicable

Not yet recruiting

Conditions: Bicep Tendon Rupture
Patellofemoral Joint Dislocation

Interventions: Other: Physical Therapy
Other: Blood Flow Restriction (BFR) Therapy

First Posted Date: 2022-05-16

Last Posted Date: 2025-04-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 68

Registration Number: NCT05375071

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

Phase 2

Conditions: Cardiomyopathy
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo
Behavioral: Counselling on healthy lifestyle intervention

First Posted Date: 2022-05-12

Last Posted Date: 2025-04-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 81

Registration Number: NCT05371496

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study

Not Applicable

Completed

Conditions: Obstructive Sleep Apnea
Snoring

Interventions: Device: Myofunctional therapy (MT) nozzle
Other: Placebo nozzle

First Posted Date: 2022-05-12

Last Posted Date: 2025-04-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 43

Registration Number: NCT05371509

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy